68Ga-PSMA-617 PET/CT与68Ga-RM2 PET/CT在适合根治性前列腺切除术的局限性前列腺癌患者中的比较:一项前瞻性、单臂、单中心II期研究
这项前瞻性单中心诊断性横断面影像研究对22例新诊断、活检证实的前列腺癌患者行68Ga-PSMA-617 PET/CT与68Ga-RM2 PET/CT配对检查,以组织学为参考。病灶分析中68Ga-PSMA-617检出74.3%(26/35)的肿瘤病灶,68Ga-RM2检出78.1%(25/32)。结论认为68Ga-PSMA-617 PET/CT有助于显示ISUP评分更高、更具临床意义的病灶,而68Ga-RM2 PET/CT对低ISUP肿瘤检出率更高,两者联合可更好分类前列腺内病灶。
要点
- 22例患者中68Ga-PSMA-617检出74.3%(26/35)病灶,68Ga-RM2检出78.1%(25/32)病灶。
- 配对分析中21/32(65.6%)病灶两示踪剂均阳性,5/32(15.6%)均阴性,6/32(18.8%)摄取不一致。
- 68Ga-PSMA-617在ISUP≥4时的摄取高于ISUP≥1(P<0.0001)和ISUP≥2(P=0.0002)。
核心结论
- 68Ga-PSMA-617 PET/CT有助于显示ISUP评分更高、更具临床意义的病灶。
- 68Ga-RM2 PET/CT对低ISUP肿瘤的检出率更高。
- 联合PSMA PET与GRP-R PET可更好地分类前列腺内病灶。
研究设计与样本
- 前瞻性、单中心、诊断性横断面影像研究,采用匿名、设盲、独立判读的配对PET/CT检查。
- 纳入22例新诊断、活检证实的前列腺癌患者,均未接受新辅助激素治疗或化疗,均行扩大盆腔淋巴结清扫,以组织学为参考。
- 患者接受68Ga-PSMA-617(放射性标记的PSMA抑制剂)与68Ga-RM2(放射性标记的GRP-R拮抗剂)PET/CT。
主要发现
- 病灶分析(包括<0.1 cm³病灶)中,68Ga-PSMA-617 PET/CT检出74.3%(26/35)的肿瘤病灶,68Ga-RM2 PET/CT检出78.1%(25/32;1例患者未能接受68Ga-RM2 PET/CT)。
- 配对检查显示,32个病灶中21个(65.6%)两种示踪剂均阳性摄取,5个(15.6%)均阴性摄取,6个(18.8%)摄取不一致。
- ISUP评分≥4时68Ga-PSMA-617摄取高于ISUP≥1(P<0.0001)及ISUP≥2(P=0.0002)。
- 68Ga-RM2在各ISUP评分间的摄取无显著差异。
- ISUP-2亚组中68Ga-RM2 SUVmax中位数显著高于68Ga-PSMA-617 SUVmax中位数(P=0.01)。
关键数值与推荐
- 美国国家综合癌症网络(NCCN)指南认可PSMA PET/CT用于高危原发性前列腺癌的初始分期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Considering the wide range of therapeutic options for localized prostate cancer (e.g., active surveillance, radiation-beam therapy, focal therapy, and radical prostatectomy), accurate assessment of the aggressiveness and localization of primary prostate cancer lesions is essential for treatment decision making. National Comprehensive Cancer Network guidelines recognize prostate-specific membrane antigen (PSMA) PET/CT for use in initial staging of high-risk primary prostate cancer. The gastrin-releasing peptide receptor (GRP-R) is a neuropeptide receptor overexpressed by low-risk prostate cancer cells. We aimed to perform the first (to our knowledge) prospective head-to-head comparison of PSMA- and GRP-R-targeted imaging at initial staging to understand how PSMA PET and GRP-R PET can be used or combined in clinical practice. Methods: This was a prospective, single-center, diagnostic cross-sectional imaging study using anonymized, masked, and independent interpretations of paired PET/CT studies in 22 patients with 68Ga-PSMA-617 (a radiolabeled PSMA inhibitor) and 68Ga-RM2 (68Ga-DOTA-4-amino-1-carboxymethylpiperidine-d-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2, a radiolabeled GRP-R antagonist). We enrolled patients with newly diagnosed, biopsy-proven prostate cancer. None had received neoadjuvant hormone therapy or chemotherapy, and all underwent extended pelvic lymph node dissection. Histologic findings served as a reference. Results: On a lesion-based analysis (including lesions < 0.1 cm3), 68Ga-PSMA-617 PET/CT detected 74.3% (26/35) of all tumor lesions and 68Ga-RM2 PET/CT detected 78.1% (25/32; 1 patient could not be offered 68Ga-RM2 PET/CT). Paired examinations showed positive uptake of the 2 tracers in 21 of 32 lesions (65.6%), negative uptake in 5 of 32 lesions (15.6%), and discordant uptake in 6 of 32 lesions (18.8%). Uptake of 68Ga-PSMA-617 was higher when the International Society of Urological Pathology (ISUP) score was at least 4 versus at least 1 (P < 0.0001) or 2 (P = 0.0002). There were no significant differences in uptake between ISUP scores for 68Ga-RM2. Median 68Ga-RM2 SUVmax was significantly higher than median 68Ga-PSMA-617 SUVmax in the ISUP-2 subgroup (P = 0.01). Conclusion: 68Ga-PSMA-617 PET/CT is useful to depict higher, more clinically significant ISUP score lesions, and 68Ga-RM2 PET/CT has a higher detection rate for low-ISUP tumors. Combining PSMA PET and GRP-R PET allows for better classification of intraprostatic lesions.
引用
- Schollhammer R, Robert G, Asselineau J, et al. Comparison of 68Ga-PSMA-617 PET/CT and 68Ga-RM2 PET/CT in Patients with Localized Prostate Cancer Who Are Candidates for Radical Prostatectomy: A Prospective, Single-Arm, Single-Center, Phase II Study. J Nucl Med. 2022. PMID: 36215569. doi:10.2967/jnumed.122.263889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。